The histone deacetylase inhibitor trichostatin A suppresses murine innate allergic inflammation by blocking group 2 innate lymphoid cell (ILC2) activation

Thorax

Volumn 71, Issue 7, 2016, Pages 633-645

  Toki, Shinji ^a   Goleniewska, Kasia ^a   Reiss, Sara ^a   Zhou, Weisong ^a   Newcomb, Dawn C ^a   Bloodworth, Melissa H ^a   Stier, Matthew T ^a   Boyd, Kelli L ^a   Polosukhin, Vasiliy V ^a   Subramaniam, Sriram ^b   Peebles, R Stokes ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EOTAXIN; EOTAXIN 2; INTERLEUKIN 13; INTERLEUKIN 33; INTERLEUKIN 5; TRICHOSTATIN A; ALLERGEN; CCL11 PROTEIN, MOUSE; CCL24 PROTEIN, MOUSE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID;

ALLERGIC AIRWAY INFLAMMATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; EOSINOPHIL; FEMALE; GENE EXPRESSION REGULATION; IMMUNE RESPONSE; INNATE IMMUNITY; LUNG HOMOGENATE; LUNG LAVAGE; LYMPHOID CELL; MOUSE; MUCUS SECRETION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; ALTERNARIA; ANIMAL; BAGG ALBINO MOUSE; IMMUNOLOGY; LUNG; LYMPHOCYTE; METABOLISM;

ALLERGENS; ALTERNARIA; ANIMALS; ASTHMA; BRONCHOALVEOLAR LAVAGE; CHEMOKINE CCL11; CHEMOKINE CCL24; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; IMMUNITY, INNATE; INTERLEUKIN-13; INTERLEUKIN-33; INTERLEUKIN-5; LUNG; LYMPHOCYTES; MICE; MICE, INBRED BALB C;

EID: 84964584567     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2015-207728     Document Type: Article

References (42)

1. Postma DS, Timens W. Remodeling in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006;3:434-9.
2. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 2008;8:183-92.
3. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012;18:716-25.
4. Neill DR, Wong SH, Bellosi A, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 2010;464:1367-70.
5. Halim TYF, Kraub RH, Sun AC, et al. Lung Natural Helper Cells Are a Critical Source of Th2 Cell-Type Cytokines in Protease Allergen-Induced Airway Inflammation. Immunity 2012;36:451-63.
6. Barlow JL, McKenzie ANJ. Type-2 innate lymphoid cells in human allergic disease. Curr Opin Allergy Clin Immunol 2014;14:397-403.
7. Snelgrove RJ, Gregory LG, Peiró T, et al. Alternaria-derived serine protease activity drives IL-33-mediated asthma exacerbations. J Allergy Clin Immunol 2014;134:583-92.e6.
8. Kabata H, Moro K, Fukunaga K, et al. Thymic stromal lymphopoietin induces corticosteroid resistance in natural helper cells during airway inflammation. Nat Commun 2013;4:2675.
9. Adcock IM, Tsaprouni L, Bhavsar P, et al. Epigenetic regulation of airway inflammation. Curr Opin Immunol 2007;19:694-700.
10. Dekker FJ, van den Bosch T, Martin NI. Small molecule inhibitors of histone acetyltransferases and deacetylases are potential drugs for inflammatory diseases. Drug Discov Today 2014;19:654-60.
11. Kazantsev AG, Thompson LM. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov 2008;7:854-68.
12. Kim HJ, Bae SC. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res 2011;3:166-79.
13. Mottamal M, Zheng S, Huang TL, et al. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules 2015;20:3898-941.
14. Chen Lf, Fischle W, Verdin E, et al. Duration of nuclear NF-kappa B action regulated by reversible acetylation. Science 2001;293:1653-7.
15. Adam E, Quivy V, Bex F, et al. Potentiation of tumor necrosis factor-induced NF-?B activation by deacetylase inhibitors is associated with a delayed cytoplasmic reappearance of I?Ba. Mol Cell Biol 2003;23:6200-9.
16. Gilmour PS, Rahman I, Donaldson K, et al. Histone acetylation regulates epithelial IL-8 release mediated by oxidative stress from environmental particles. Am J Physiol Lung Cell Mol Physiol 2003;284:L533-40.
17. Han SB, Lee JK. Anti-inflammatory effect of Trichostatin-A on murine bone marrow-derived macrophages. Arch Pharm Res 2009;32:613-24.
18. Halili MA, Andrews MR, Labzin LI, et al. Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS. J Leukoc Biol 2010;87:1103-14.
19. Suh HS, Choi S, Khattar P, et al. Histone deacetylase inhibitors suppress the expression of inflammatory and innate immune response genes in human microglia and astrocytes. J Neuroimmune Pharmacol 2010;5:521-32.
20. Choi JH, Oh SW, Kang MS, et al. Trichostatin A attenuates airway inflammation in mouse asthma model. Clin Exp Allergy 2005;35:89-96.
21. Royce SG, Dang W, Yuan G, et al. Effects of the histone deacetylase inhibitor, Trichostatin A, in a chronic allergic airways disease model in mice. Arch Immunol Ther Exp (Warsz) 2012;60:295-306.
22. Banerjee A, Trivedi CM, Damera G, et al. Trichostatin A abrogates airway constriction, but not inflammation, in murine and human asthma models. Am J Respir Cell Mol Biol 2012;46:132-8.
23. Hardman CS, Panova V, McKenzie ANJ. IL-33 citrine reporter mice reveal the temporal and spatial expression of IL-33 during allergic lung inflammation. Eur J Immunol 2013;43:488-98.
24. Denzler KL, Farmer SC, Crosby JR, et al. Eosinophil major basic protein-1 does not contribute to allergen-induced airway pathologies in mouse models of asthma. J Immunol 2000;165:5509-17.
25. Zhu Z, Homer RJ, Wang Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999;103:779-88.
26. Cayrol C, Girard JP. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol 2014;31:31-7.
27. Willart MA, Deswarte K, Pouliot P, et al. Interleukin-1a controls allergic sensitization to inhaled house dust mite via the epithelial release of GM-CSF and IL-33. J Exp Med 2012;209:1505-17.
28. Licciardi PV, Karagiannis TC. Regulation of Immune Responses by Histone Deacetylase Inhibitors. ISRN Hematology 2012;2012:1-10.
29. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 1998;12:599-606.
30. Deckert J, Struhl K. Histone acetylation at promoters is differentially affected by specific activators and repressors. Mol Cell Biol 2001;21:2726-35.
31. Iwabata H, Yoshida M, Komatsu Y. Proteomic analysis of organ-specific post-Translational lysine-Acetylation and-methylation in mice by use of anti-Acetyl lysine and-methyl lysine mouse monoclonal antibodies. Proteomics 2005;5:4653-64.
32. Lin HS, Hu CY, Chan HY, et al. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol 2007;150:862-72.
33. Shi YL, Gu J, Park JJ, et al. Histone deacetylases inhibitor Trichostatin A ameliorates DNFB-induced allergic contact dermatitis and reduces epidermal Langerhans cells in mice. J Dermatol Sci 2012;68:99-107.
34. Vigushin DM, Ali S, Pace PE, et al. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 2001;7:971-6.
35. Palmer G, Gabay C. Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol 2011;7:321-9.
36. Pastorelli L, De Salvo C, Cominelli MA, et al. Novel cytokine signaling pathways in inflammatory bowel disease: insight into the dichotomous functions of IL-33 during chronic intestinal inflammation. Therap Adv Gastroenterol 2011;4:311-23.
37. Duan L, Chen J, Gong F, et al. The role of IL-33 in rheumatic diseases. Clin Dev Immunol 2013;2013:1-5.
38. Vishwakarma S, Iyer LR, Muley M, et al. Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects. Int Immunopharmacol 2013;16:72-8.
39. Tsuji G, Okiyama N, Villarroel VA, et al. Histone deacetylase 6 inhibition impairs effector CD8 T-cell functions during skin inflammation. J Allergy Clin Immunol 2015;135:1228-39.
40. Olzmann JA, Li L, Chin LS. Aggresome formation and neurodegenerative diseases: therapeutic implications. Curr Med Chem 2008;15:47-60. .
41. Kovacs JJ, Murphy PJM, Gaillard S, et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005;18:601-7.
42. Valenzuela-Fernández A, Cabrero JR, Serrador JM, et al. HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol 2008;18:291-7.